{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resected+Stage&page=22",
    "query": {
      "condition": "Resected Stage",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 544,
    "total_pages": 55,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resected+Stage&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resected+Stage&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T13:18:24.868Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03583710",
      "title": "Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ENSAT Stage I Adrenal Cortex Carcinoma",
        "ENSAT Stage II Adrenal Cortex Carcinoma",
        "ENSAT Stage III Adrenal Cortex Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Mitotane",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2018-08-20",
      "completion_date": "2029-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-24T13:18:24.868Z",
      "location_count": 3,
      "location_summary": "Ann Arbor, Michigan • St Louis, Missouri • Houston, Texas",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03583710"
    },
    {
      "nct_id": "NCT02696356",
      "title": "Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "GRN-1201",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BrightPath Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2016-04",
      "completion_date": "2018-03",
      "has_results": false,
      "last_update_posted_date": "2018-06-14",
      "last_synced_at": "2026-10-24T13:18:24.868Z",
      "location_count": 4,
      "location_summary": "Cincinnati, Ohio • Portland, Oregon • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02696356"
    },
    {
      "nct_id": "NCT02320305",
      "title": "MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Stage IIA Skin Melanoma",
        "Stage IIB Skin Melanoma",
        "Stage IIC Skin Melanoma",
        "Stage IIIA Skin Melanoma",
        "Stage IIIB Skin Melanoma",
        "Stage IIIC Skin Melanoma",
        "Stage IV Skin Melanoma"
      ],
      "interventions": [
        {
          "name": "MART-1 Antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TLR4 Agonist GLA-SE",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2015-01-27",
      "completion_date": "2019-04-11",
      "has_results": false,
      "last_update_posted_date": "2020-01-14",
      "last_synced_at": "2026-10-24T13:18:24.868Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02320305"
    },
    {
      "nct_id": "NCT05526755",
      "title": "A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage II-IIIB Non-small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Osimertinib 80 mg/40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 188,
      "start_date": "2023-03-06",
      "completion_date": "2029-11-22",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-24T13:18:24.868Z",
      "location_count": 3,
      "location_summary": "Santa Rosa, California • Las Vegas, Nevada • White Plains, New York",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "White Plains",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05526755"
    },
    {
      "nct_id": "NCT07217470",
      "title": "Fluid Status of ESRD Patients Undergoing Dialysis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "ESRD (End Stage Renal Disease)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "HemoCept Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 26,
      "start_date": "2025-08-18",
      "completion_date": "2025-11-20",
      "has_results": false,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-10-24T13:18:24.868Z",
      "location_count": 1,
      "location_summary": "Reno, Nevada",
      "locations": [
        {
          "city": "Reno",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07217470"
    },
    {
      "nct_id": "NCT04594772",
      "title": "Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreas Cancer"
      ],
      "interventions": [
        {
          "name": "Folfirinox",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Pancreatectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2021-03-17",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-24T13:18:24.868Z",
      "location_count": 2,
      "location_summary": "Tucson, Arizona • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04594772"
    },
    {
      "nct_id": "NCT00025181",
      "title": "Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Intraocular Melanoma",
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "MART-1 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp100 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "incomplete Freund's adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tyrosinase peptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 19,
      "start_date": "2001-10",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2014-05-22",
      "last_synced_at": "2026-10-24T13:18:24.868Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00025181"
    },
    {
      "nct_id": "NCT06205485",
      "title": "Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Fluoruracil",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Canadian Cancer Trials Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2024-06-26",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-10-24T13:18:24.868Z",
      "location_count": 105,
      "location_summary": "Phoenix, Arizona • Irvine, California • Los Angeles, California + 86 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06205485"
    },
    {
      "nct_id": "NCT05120947",
      "title": "Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Resectable Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "42 Gy Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "39 Gy Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "32.5 Gy Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2021-12-01",
      "completion_date": "2025-11-22",
      "has_results": true,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-10-24T13:18:24.868Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05120947"
    },
    {
      "nct_id": "NCT00636168",
      "title": "Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "High Risk Stage III Melanoma"
      ],
      "interventions": [
        {
          "name": "ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1211,
      "start_date": "2008-06-30",
      "completion_date": "2018-11-26",
      "has_results": true,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-10-24T13:18:24.868Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00636168"
    }
  ]
}